EGFR and Lung Cancer - American Lung Association
2025年1月22日 · EGFR-positive lung cancer represents about 10-15% of lung cancers in the United States and most often appears in the adenocarcinoma subtype of non-small cell lung …
The changing treatment landscape of EGFR -mutant non-small-cell lung cancer
2024年11月29日 · Third-generation EGFR tyrosine-kinase inhibitors (TKIs) have become the standard-of-care first-line treatment for advanced-stage EGFR -mutant non-small-cell lung cancer (NSCLC).
Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung …
Epidermal growth factor receptor (EGFR) mutations are the most common oncogenic drivers in non-small-cell lung cancer (NSCLC). Significant developments have taken place which highlight the differences in tumor biology that exist between the mutant and wild-type subtypes of NSCLC.
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
The discovery of the association between EGFR mutations and the efficacy of EGFR tyrosine-kinase inhibitors (TKIs) has revolutionized the treatment paradigm for patients with non-small-cell lung cancer (NSCLC). Currently, third-generation EGFR TKIs, which are often characterized by potent central ne …
EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to …
About 10–30% of patients with non-small cell lung cancer (NSCLC) harbor mutations of the EGFR gene. The Tumor Microenvironment (TME) of patients with NSCLC harboring EGFR mutations displays peculiar characteristics and may modulate the antitumor immune response.
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 …
Molecular testing is performed upon diagnosis of non-small cell lung cancer (NSCLC) because of the large success of targeted therapies for oncogenic mutations. Epidermal growth factor receptor (EGFR) mutations are the most commonly identified ...
EGFR Mutations in Non–Small-Cell Lung Cancer - JAMA Network
Follow-up studies directly comparing the 2 treatment strategies in patients with advanced-stage non–small-cell lung cancer harboring activating EGFR mutations confirmed the superiority of EGFR TKI therapy to chemotherapy in this patient population as described herein.
ESMO expert consensus statements on the management of EGFR mutant non ...
The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer in 2021. The consensus included a multidisciplinary panel of 34 leading …
Advancement of First-Line Treatments on EGFR-Mutated NSCLC
2025年1月17日 · As part of a Satellite Sessions program focused on the Cleveland Clinic and surrounding institutions, CancerNetwork hosted a panel discussion on treatment options for patients with EGFR -mutated non–small cell lung cancer (NSCLC). The program was brought together to discuss the use of blood and tissue biopsies in testing for atypical mutations in patients with EGFR -mutated NSCLC ...
The Role of EGFR Mutations in Non-Small-Cell Lung Cancer Treatments - WebMD
2024年10月29日 · EGFR, epidermal growth factor receptor, is a protein found on the surface of your cells that makes them grow. If you have non-small-cell lung cancer (NSCLC),...